Please use this identifier to cite or link to this item:
|Title:||Immunogenicity and immunization costs of adjuvanted versus non-adjuvanted hepatitis B vaccine in chronic kidney disease patients|
García-Basteiro, Alberto L.
Bayas Rodríguez, José María
Malalties del ronyó
|Publisher:||Taylor & Francis|
|Abstract:||Hepatitis B virus (HBV) vaccination is recommended for all susceptible chronic pre-hemodialysis and hemodialysis patients. This study assessed the immunogenicity of HBV vaccines (adjuvanted and non-adjuvanted) in chronic kidney disease patients vaccinated at the Hospital Clinic of Barcelona (Spain) between January 2007 and July 2012. In addition, the costs for the health system were evaluated according to the proportion of vaccine responders after receiving either vaccine. Patients receiving three doses of hepatitis B adjuvanted vaccine were three times more likely to seroconvert than patients immunized with non-adjuvanted vaccines, OR 3.56 (95% CI 1.84-6.85). This resulted in fewer patients requiring a second course of HBV vaccination and fewer outpatient visits, saving more than euro9,500 per 100 patients. The higher immunogenicity of the adjuvanted HBV vaccine would counterbalance the lower costs associated with the non-adjuvanted vaccine.|
|Note:||Versió postprint del document publicat a: http://dx.doi.org/10.1080/21645515.2016.1168955|
|It is part of:||Human Vaccines & Immunotherapeutics, 2016|
|Appears in Collections:||Articles publicats en revistes (ISGlobal)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.